Preliminary Trends of the EORTC Study Comparing Postoperative Chemotherapy, Immunotherapy, Chemoimmunotherapy or Abstention in Squamous Cell Bronchial Carcinoma
This is a very short interim report since, due to the stratification according to nodal status and the first random allocation to groups with and without radiotherapy, there are 16 subgroups among 310 patients available for analysis. For this reason, the EORTC expects no conclusive results before 2 additional years of follow-up. Nevertheless, some trends are beginning to appear that will be summarized below and should be considered as very preliminary.
KeywordsMinimal Residual Disease Random Allocation Conclusive Result Minimal Residual Medical Treatment Group
- 1.Israel, L.: Nonspecific immunostimulation in bronchogenic cancer. Scand. J. Resp. Dis. [Suppl.] 89, 95–105 (1974).Google Scholar
- 2.Israel, L., Edelstein, R., Depierre, A., Dimitrov, N.: Daily intravenous infusions of Corynebacterium parvum in twenty patients with disseminated cancer: A preliminary report of clinical and biologic findings. J.N.C.I. 55, 29–33 (1975).Google Scholar
- 3.Israel, L.: Nonspecific immune stimulation with corynebacteria in lung cancer. In: Lung cancer. Natural history, prognosis, and therapy. Israël, L., Chahinian, P. (eds.), Vol. I, pp. 273-280. New York-London: Academic Press 1976.Google Scholar
- 5.Israel, L.: An immunological look at the TNM classification therapeutic implications and strategies. Cancer Treat. Rep. (1978) (in press).Google Scholar
- 6.McKneally, M. F., Maver, C., Kansel, H. W.: Regional immunotherapy of lung cancer with intrapleural BCG. Lancet 1976/I, 377-379.Google Scholar